What's moving this stock lately
1 direct · 0 2nd-order · 0 thematicRanked by relevance and recency.
- #1Impact0.49%bullishDirectRYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 202623d ago
RYBREVANT and LAZCLUZE are oncology growth drivers; lower adverse-event rates aid uptake, but the effect is small relative to J&J's overall scale
Also named: AZN
🎯 Market expectations
Estimate coverage Medium · 60/100Nasdaq analyst consensus · the pre-news baseline
- Jun 2026$2.90 vs $2.84+2.11%
- Mar 2026$2.70 vs $2.67+1.12%
- Dec 2025$2.46 vs $2.43+1.23%
- Sep 2025$2.80 vs $2.77+1.08%
The takeaway
It has tracked consensus closely — no systematic over- or under-shooting.
Analyst estimates, not our forecast · not investment advice
🏛️ Company factsSEC filings + FINRA official data
Annual revenue $94.2B · latest quarter up 6.6% YoY · profitable (FY net income $26.8B) · short activity below its recent average — bears covering.
FY revenue
$94.2B
2025-12
Latest Q YoY
+6.6%
Gross margin
67.9%
FY net income
$26.8B
Diluted EPS
$11.13
Short volume
30.6%
20d avg 50.1% · shorts covering
🐋 5%+ ownership filings (last 180d)
The following investors reported beneficial ownership of more than 5% in recent SEC filings. "Activist" filers stated an intent to influence control of the company; "Passive" indicates the filer did not report such an intent.
- 2026-05-01passive (13G)VANGUARD CAPITAL MANAGEMENT LLC
🕰️ Price × news · analysis history
Drag to pan, scroll to zoom · real daily bars and volume
📜 Call history (newest first
10 past analyses of this stock, each checked against what the price did afterwards · sign up to view
Start my free trialCurrent conviction
Crowding
Risk temperature
Tail risk
Triggers
Money flow
Insider signals
See every affected stock, second-order impact and risk factor. Try Pro free for 7 days — no credit card required.
Start my free trial